Unigestion Holding SA lifted its holdings in Danaher Co. (NYSE:DHR – Get Rating) by 12.4% in the fourth quarter, Holdings Channel reports. The fund owned 123,127 shares of the conglomerate’s stock after purchasing an additional 13,581 shares during the quarter. Danaher makes up 1.6% of Unigestion Holding SA’s holdings, making the stock its 26th biggest holding. Unigestion Holding SA’s holdings in Danaher were worth $40,510,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in DHR. Maryland Capital Advisors Inc. purchased a new position in shares of Danaher during the fourth quarter worth approximately $28,000. Dixon Hughes Goodman Wealth Advisors LLC purchased a new position in shares of Danaher during the fourth quarter worth approximately $29,000. Lee Financial Co purchased a new position in shares of Danaher during the fourth quarter worth approximately $30,000. Evolution Advisers Inc. purchased a new position in shares of Danaher during the fourth quarter worth approximately $32,000. Finally, Dark Forest Capital Management LP purchased a new position in Danaher during the third quarter valued at approximately $33,000. 78.42% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently issued reports on the stock. Wells Fargo & Company lowered shares of Danaher from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $330.00 to $265.00 in a report on Monday, April 25th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. Robert W. Baird cut their price target on shares of Danaher from $334.00 to $319.00 and set an “outperform” rating on the stock in a report on Friday, April 22nd. Barclays cut their price target on shares of Danaher from $355.00 to $325.00 and set an “overweight” rating on the stock in a report on Thursday, January 27th. Finally, Zacks Investment Research lowered shares of Danaher from a “buy” rating to a “hold” rating and set a $278.00 price target on the stock. in a report on Monday, April 25th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $331.14.
Danaher (NYSE:DHR – Get Rating) last posted its earnings results on Thursday, April 21st. The conglomerate reported $2.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.11. The company had revenue of $7.69 billion during the quarter, compared to the consensus estimate of $7.53 billion. Danaher had a net margin of 21.32% and a return on equity of 18.64%. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.52 earnings per share. As a group, equities research analysts anticipate that Danaher Co. will post 10.31 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Friday, June 24th will be issued a $0.25 dividend. The ex-dividend date is Thursday, June 23rd. This represents a $1.00 dividend on an annualized basis and a yield of 0.40%. Danaher’s payout ratio is 11.57%.
In other Danaher news, EVP Joakim Weidemanis sold 6,500 shares of Danaher stock in a transaction on Monday, April 25th. The shares were sold at an average price of $255.74, for a total value of $1,662,310.00. Following the completion of the transaction, the executive vice president now owns 86,398 shares of the company’s stock, valued at $22,095,424.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 11.20% of the stock is currently owned by insiders.
Danaher Company Profile (Get Rating)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.
- Get a free copy of the StockNews.com research report on Danaher (DHR)
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
- It’s A Good Time To Own Ralph Lauren (NYSE: RL)
- Block, Inc: Correcting for Negative Earnings
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.